Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS
Home/The Filing Wire/Bright Minds Biosciences Inc./ 6-K

SEC Filing · 6-K

Bright Minds Biosciences Inc.

SEC Filing

Filed May 28, 2026Accepted May 27, 2026, 8:03 PM EDTCIK 1827401Accession 0002060755-26-000031
View company →Permanent SEC source ↗
Share

Company context

Bright Minds is a biotechnology company developing innovative treatments for patients with neurological and psychiatric disorders. Our pipeline includes novel compounds targeting key receptors in the brain to address conditions with high unmet medical need, including epilepsy, Prader-Willi Syndrome, depression, and other CNS disorders. Bright Minds is focused on delivering breakthrough therapies that can transform patients' lives.

Current securities

DRUGCSE · EQUITY · CurrentDRUGNASDAQ · EQUITY · Current
Historical securities (1)
DRUGNEO · EQUITY · Historical · closed Oct 1, 2024

Recent company filings

  1. 6-K filingOct 2, 2026
  2. 6-K filingOct 1, 2026
  3. 6-K filingAug 17, 2026
  4. SCHEDULE 13G/A - filed by Cormorant Asset Management, LP regarding BRIGHT MINDS BIOSCIENCES INC.Aug 14, 2026
  5. S-8 filingAug 13, 2026

As-filed source

Primary evidence
As filedOpen full document ↗

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.